Lamotrigine

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Epilepsy, Lennox-Gastaut Syndrome, Bipolar Disorder

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
JP
  • Use as adjunctive treatment with other antiepileptic drugs for partial seizures (including secondary generalized seizures), tonic-clonic seizures, and generalized seizures associated with Lennox-Gastaut syndrome in patients with epilepsy for whom other antiepileptic drugs are not sufficiently effective
Product first approved 2008PMDA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (38)
Bipolar Disorder
NCT06929273 · Bristol-Myers Squibb
2025-07-18 – 2028-06-13 · Bipolar Disorder Type I With Mania
What this study did
NCT00723450 · GlaxoSmithKline
2008-07 – 2013-08 · Bipolar Disorder
What this study did
NCT00566020 · GlaxoSmithKline
2008-05 – 2010-10 · Bipolar Disorder
What this study did
NCT00621842 · University Hospitals Cleveland Medical Center
2008-01 – 2010-03 · Bipolar Disorder, Depression, Bipolar
What this study did
NCT00550407 · GlaxoSmithKline
2007-11 – 2009-10 · Bipolar Disorder
What this study did
NCT00221975 · University Hospitals Cleveland Medical Center
2002-07 – 2007-12 · Bipolar Disorder
What this study did
NCT00074776 · Stanford University
2003-05 – 2007-10 · Bipolar Disorder
What this study did
NCT00063362 · University Hospitals Cleveland Medical Center
2002-02 – 2007-07 · Bipolar Disorder
What this study did
NCT00226135 · University of Aarhus
2001-03 – 2006-12 · Bipolar Disorder
What this study did
NCT00224510 · GlaxoSmithKline
2002-08 – 2006-09 · Bipolar Disorder, Bipolar Depression
What this study did
NCT00056277 · GlaxoSmithKline
2003-02-27 – 2005-12-14 · Bipolar Disorder
What this study did
Epilepsy
NCT01891890 · Emory University
2013-08 – 2015-10-23 · Epilepsy, Partial, Epilepsy, Localization Related
What this study did
NCT01431963 · GlaxoSmithKline
2011-09 – 2014-10 · Epilepsy
What this study did
NCT00516139 · GlaxoSmithKline
2007-08 – 2010-07 · Epilepsy
What this study did
NCT00395694 · GlaxoSmithKline
2006-08-07 – 2009-03-26 · Epilepsy
What this study did
NCT00242606 · Philipps University Marburg
2005-03 – 2009-01 · Epilepsy
What this study did
NCT00355082 · GlaxoSmithKline
2006-05 – 2008-11 · Epilepsy, Partial
What this study did
NCT00113165 · GlaxoSmithKline
2004-10 – 2007-07 · Epilepsy, Epilepsy, Partial
What this study did
NCT00264615 · GlaxoSmithKline
2005-10 – 2006-06 · Epilepsy
What this study did
NCT00266149 · University of Aarhus
2003-06 – 2005-05 · Epilepsy
What this study did
Other / comorbidity
NCT05017155 · University College, London
2021-08-12 – 2024-04-02 · Non-Dystrophic Myotonia
What this study did
NCT03831854 · The Cleveland Clinic
2019-01-24 – 2020-12-31 · Reducing Psychological Side Effects of Ketamine
What this study did
NCT02374567 · Hannover Medical School
2015-01 – 2017-06-28 · Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
What this study did
NCT00571246 · Yale University
2012-06 – 2016-06 · Alcohol Dependence, Post Traumatic Stress Disorder
What this study did
NCT01939561 · Grete Andersen, MD
2013-11 – 2015-11 · Dystrophia Myotonica Type 1, Myotonia Congenita, Paramyotonia Congenita, Hyperkalemic Periodic Paralysis, Potassium-Aggravated Myotonia
What this study did
NCT01042496 · Mayo Clinic
2009-12 – 2014-10 · Bipolar Depression
What this study did
NCT00068445 · Alliance for Clinical Trials in Oncology
2004-02 – 2013-11 · Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00277641 · Lindner Center of HOPE
2006-03 – 2009-01 · Binge Eating Disorder, Obesity
What this study did
NCT00579982 · GlaxoSmithKline
2008-01 – 2008-02 · Mood Disorders
What this study did
NCT00652171 · Institute of Social Security of the Civil Servants of Minas Gerais
2004-01 – 2006-01 · Depression
What this study did
NCT00086593 · GlaxoSmithKline
2004-05 – 2005-07 · Schizophrenia
What this study did
NCT00071747 · GlaxoSmithKline
2003-08 – 2005-01 · Schizophrenia
What this study did
Phase 2/3 (4)
Other / comorbidity
NCT02256124 · Erasmus Medical Center
2014-10 – 2020-04 · Neurofibromatosis Type 1
What this study did
NCT02556060 · Taipei City Hospital
2015-09 – 2017-05-01 · Addiction
What this study did
NCT00913107 · University of Malaya
2007-09 – 2008-06 · Trigeminal Neuralgia
What this study did
NCT00295776 · George Washington University
2005-02 – 2007-12 · Neuralgia, Postherpetic
What this study did
Phase 2 (17)
Bipolar Disorder
NCT00475137 · University of British Columbia
2007-12 – 2015-06 · Bipolar II Disorder, Most Recent Episode Major Depressive
What this study did
NCT00176228 · University of Illinois at Chicago
2004-02 – 2008-01 · Bipolar Disorder
What this study did
NCT00206778 · Beth Israel Medical Center
2003-07 – 2007-07 · Mixed Mania Bipolar Disorder
What this study did
Epilepsy
NCT03220256 · Seoul National University Hospital
2016-08-02 – 2018-08-01 · Lamotrigine Allergy
What this study did
NCT00044278 · GlaxoSmithKline
2000-09 – 2006-06 · Epilepsy
What this study did
NCT00043875 · GlaxoSmithKline
2000-05 – 2003-11 · Epilepsy
What this study did
Other / comorbidity
NCT05420350 · Dent Neuroscience Research Center
2020-12-16 – 2024-12 · Meniere Disease, Ménière's Vertigo, Vertigo, Intermittent, Vertigo, Aural
What this study did
NCT04770493 · Brown University
2022-01-24 – 2024-10-24 · Alcohol Use Disorder
What this study did
NCT03504501 · Technical University of Munich
2019-03-22 – 2023-10-31 · Impaired Synaptic Plasticity, Impaired Cognition
What this study did
NCT02158585 · Dent Neuroscience Research Center
2014-06 – 2017-03 · Meniere's Disease, Ménière's Vertigo, Vertigo, Intermittent, Vertigo, Aural
What this study did
NCT00917839 · Cantonal Hospital of St. Gallen
2009-06 – 2011-12 · Relapsing-Remitting Multiple Sclerosis
What this study did
NCT00513019 · University of Chicago
2007-08 – 2009-09 · Neurotic Excoriation, Pathologic Skin Picking, Psychogenic Excoriation, Dermatillomania
What this study did
NCT00257855 · University College London Hospitals
2005-11 – 2009-02 · Secondary Progressive Multiple Sclerosis
What this study did
NCT00269594 · University of Minnesota
2006-01 – 2006-09 · Neurotic Disorders, Obsessive-Compulsive Disorder
What this study did
NCT00001482 · National Institute of Mental Health (NIMH)
1995-05 – 2001-05 · Anxiety Disorder, Mood Disorder, Psychotic Disorder
What this study did
NCT00015106 · National Institute on Drug Abuse (NIDA)
1997-11 – 1999-02 · Cocaine-Related Disorders
What this study did
NCT00000192 · Yale University
1993-01 – 1998-01 · Opioid-Related Disorders
What this study did
Phase 1/2 (1)
Bipolar Disorder
NCT00789113 · University of Minnesota
2008-11 – 2011-01 · Epilepsy, Seizures, Bipolar Disorder, Bipolar Depression
What this study did
Phase 1 (44)
Bipolar Disorder
NCT02513654 · GlaxoSmithKline
2015-09-06 – 2015-11-11 · Bipolar Disorder
What this study did
NCT00488566 · Biogen
2007-05-31 – 2008-05-31 · Bipolar Disorder
What this study did
Epilepsy
NCT03695094 · UCB Biopharma S.P.R.L.
2018-09-18 – 2019-05-30 · Epilepsy
What this study did
NCT02707965 · Food and Drug Administration (FDA)
2017-06-08 – 2018-09-04 · Epilepsy
What this study did
NCT02064465 · GlaxoSmithKline
2014-03-15 – 2014-07-08 · Epilepsy
What this study did
NCT01357902 · GlaxoSmithKline
2011-04-18 – 2011-05-23 · Epilepsy
What this study did
NCT00627575 · GlaxoSmithKline
2008-02-04 – 2008-09-12 · Epilepsy
What this study did
NCT00605371 · GlaxoSmithKline
2008-01-15 – 2008-03-06 · Epilepsy
What this study did
NCT00412191 · GlaxoSmithKline
2007-02-06 – 2007-04-27 · Epilepsy
What this study did
NCT02283801 · Bial - Portela C S.A.
2006-11 – 2007-01 · Epilepsy
What this study did
NCT00144872 · GlaxoSmithKline
2004-11-01 – 2006-04-22 · Seizure, Absence
What this study did
Other / comorbidity
NCT06729970 · Karuna Therapeutics, Inc., a Bristol Myers Squibb company
2024-12-26 – 2026-01-23 · Healthy Volunteers
What this study did
NCT06199791 · Desitin Arzneimittel GmbH
2023-04-03 – 2023-06-14 · Fasting
What this study did
NCT04602221 · Boehringer Ingelheim
2020-12-01 – 2022-08-12 · Healthy
What this study did
NCT04938856 · University of Karachi
2020-09-04 – 2020-10-25 · Bioequivalence
What this study did
NCT02708849 · Yale University
2015-06 – 2020-03 · Mental Disorders
What this study did
NCT04015687 · Agios Pharmaceuticals, Inc.
2019-07-15 – 2019-10-09 · Healthy Participants
What this study did
NCT03898011 · Pharmtechnology LLC
2019-03-23 – 2019-05-04 · Healthy Adults
What this study did
NCT05145608 · Alembic Pharmaceuticals Ltd.
2018-01-10 – 2018-02-21 · Bioequivalence
What this study did
NCT02821338 · Food and Drug Administration (FDA)
2016-06 – 2017-04 · Healthy
What this study did
NCT01618799 · IPCA Laboratories Ltd.
2012-03 – 2012-05 · Fasting State
What this study did
NCT01618825 · IPCA Laboratories Ltd.
2012-03 – 2012-05 · Fed
What this study did
NCT01888757 · Dr. Reddy's Laboratories Limited
2010-09 – 2010-10 · Healthy
What this study did
NCT01888263 · Dr. Reddy's Laboratories Limited
2010-08 – 2010-09 · Healthy
What this study did
NCT01888731 · Dr. Reddy's Laboratories Limited
2010-08 – 2010-09 · Healthy
What this study did
NCT01888250 · Dr. Reddy's Laboratories Limited
2010-08 – 2010-09 · Healthy
What this study did
NCT00618241 · Radboud University Medical Center
2008-02 – 2008-10 · HIV Infection
What this study did
NCT01607086 · GlaxoSmithKline
2008-07-11 – 2008-07-18 · Mental Disorders
What this study did
NCT00449774 · GlaxoSmithKline
2007-05-07 – 2007-06-19 · Mental Disorders
What this study did
NCT00410371 · GlaxoSmithKline
2006-12-28 – 2007-01-25 · Mental Disorders
What this study did
NCT00647751 · Mylan Pharmaceuticals Inc
2004-08 – 2004-08 · Healthy
What this study did
NCT00650208 · Mylan Pharmaceuticals Inc
2004-07 – 2004-08 · Healthy
What this study did
NCT01131975 · Dr. Reddy's Laboratories Limited
2003-01 – 2003-03 · Healthy
What this study did
NCT01131949 · Dr. Reddy's Laboratories Limited
2003-01 – 2003-03 · Healthy
What this study did
NCT01513720 · Dr. Reddy's Laboratories Limited
2002-12 – 2002-12 · Healthy
What this study did
NCT01513681 · Dr. Reddy's Laboratories Limited
2002-11 – 2002-11 · Healthy
What this study did
NCT00838136 · Teva Pharmaceuticals USA
2002-02 – 2002-03 · Healthy
What this study did
NCT00838279 · Teva Pharmaceuticals USA
2002-02 – 2002-03 · Healthy
What this study did
NCT00835263 · Teva Pharmaceuticals USA
2002-01 – 2002-02 · Healthy
What this study did
NCT00834561 · Teva Pharmaceuticals USA
2002-01 – 2002-02 · Healthy
What this study did
Phase 4 (36)
Bipolar Disorder
NCT02389712 · Mayo Clinic
2015-03 – 2018-05-23 · Bipolar Disorder
What this study did
NCT02989727 · University of Saskatchewan
2003-11 – 2017-12 · Depression, Bipolar Disorder, Bipolar Depression, Melancholia, Lamotrigine
What this study did
NCT01588457 · The University of Texas Health Science Center at San Antonio
2011-06 – 2016-12 · Bipolar I Disorder, Bipolar II Disorder
What this study did
NCT01015586 · Medical University of South Carolina
2010-02 – 2014-09 · Alcohol Dependence, Bipolar Disorder, Depression, Mania, Psychosis
What this study did
NCT01864551 · Tri-Service General Hospital (TSGH)
2008-08 – 2012-09 · Bipolar Disorder
What this study did
NCT00280293 · University of Texas Southwestern Medical Center
2006-03 – 2010-01 · Bipolar Disorder, Cocaine Dependence
What this study did
NCT00277212 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2005-12-01 – 2009-07-01 · Bipolar Disorder
What this study did
NCT00183469 · The University of Texas Health Science Center at San Antonio
2004-12 – 2009-04 · Bipolar Disorder, Depression
What this study did
NCT00181844 · Massachusetts General Hospital
2005-01 – 2008-04 · Bipolar Disorder, Mania
What this study did
NCT00223509 · The University of Texas Health Science Center at San Antonio
2005-08 – 2007-11 · Bipolar Disorder
What this study did
NCT00360126 · GlaxoSmithKline
2005-10 – 2007-02 · Bipolar Disorder
What this study did
NCT00188643 · University Health Network, Toronto
2002-01 – 2007-01 · Bipolar Disorder
What this study did
NCT00485771 · Eli Lilly and Company
2003-11 – 2005-01 · Bipolar Disorder
What this study did
NCT00067938 · GlaxoSmithKline
2003-08 – 2004-08 · Bipolar Disorder
What this study did
NCT00177567 · University of Pittsburgh
2001-07 – 2004-01 · Bipolar Disorder
What this study did
Epilepsy
NCT05881928 · Assiut University
2024-07-29 – 2025-04 · Epilepsy, Lamotrigine, Sodium Valproate Adverse Reaction
What this study did
NCT03689114 · Mario Negri Institute for Pharmacological Research
2021-05-10 – 2024-06-30 · Epilepsies, Partial
What this study did
NCT05748236 · Dhaka Medical College
2022-11-01 – 2023-10 · Focal Epilepsy
What this study did
NCT01733394 · University of Cincinnati
2012-12-12 – 2016-09-26 · Epilepsy
What this study did
NCT02404168 · University of Maryland, Baltimore
2015-07-07 – 2016-04-06 · Epilepsy
What this study did
NCT01713777 · University of Cincinnati
2013-04 – 2015-09 · Epilepsy
What this study did
NCT01995825 · University of Maryland, Baltimore
2012-05 – 2013-10 · Epilepsy
What this study did
NCT00807989 · Yonsei University
2008-03 – 2012-05 · Epilepsy
What this study did
NCT00438451 · Johannes Gutenberg University Mainz
2007-01 – 2011-08 · Focal Epilepsy
What this study did
NCT00896987 · Korean Epilepsy Society
2006-05 – 2008-12 · Epilepsy
What this study did
NCT00137709 · Chinese University of Hong Kong
2004-11 – 2008-07 · Epilepsy
What this study did
NCT00043901 · GlaxoSmithKline
2000-12-01 – 2005-03-01 · Epilepsy, Tonic-Clonic
What this study did
NCT00043914 · GlaxoSmithKline
2002-01-14 – 2003-01-29 · Epilepsy
What this study did
Other / comorbidity
NCT01142310 · University of Texas Southwestern Medical Center
2010-06 – 2015-06 · Memory Impairment
What this study did
NCT02303106 · Per Damkier
2014-11 – 2015-04 · Healthy
What this study did
NCT00419003 · Baylor College of Medicine
2006-12 – 2008-09 · Major Depression
What this study did
NCT00634062 · Mclean Hospital
2004-12 – 2007-09 · Borderline Personality Disorder
What this study did
NCT00947375 · Central Mental Clinic for Outpatients of Baku City
2005-01 – 2007-01 · Schizophrenia
What this study did
NCT00223262 · University of Texas Southwestern Medical Center
2002-08 – 2005-09 · Memory Impairment Due to Corticosteroid Use, Hypomania Due to Corticosteroid Use, Hippocampal Atrophy Due to Corticosteroid
What this study did
NCT00153244 · Centre of Chinese Medicine, Georgia
2002-08 – 2003-05 · Bronchial Asthma
What this study did
Early phase / not applicable (14)
Bipolar Disorder
NCT01880957 · Stony Brook University
2011-11-08 – 2017-06-23 · Bipolar Disorder, Bipolar Depression, Unipolar Depression
What this study did
NCT01463111 · Emory University
2011-05 – 2016-04 · Bipolar Disorder
What this study did
NCT00012558 · National Institute of Mental Health (NIMH)
1998-09 – 2005-09 · Bipolar Disorder
What this study did
Epilepsy
NCT04939675 · National Taiwan University Hospital
2021-07-01 – 2025-06-30 · Epilepsy
What this study did
NCT00916149 · Massachusetts General Hospital
2007-01 – 2012-10 · Epilepsy
What this study did
NCT00208520 · Dutch Epilepsy Clinics Foundation
2003-07 – 2007-06 · Adults With Tonic Clonic Seizures and/or Partial Seizures
What this study did
Other / comorbidity
NCT05639257 · Grete Andersen, MD
2022-12-05 – 2024-04-01 · Non-Dystrophic Myotonia
What this study did
NCT04156035 · Charite University, Berlin, Germany
2020-03-10 – 2020-12-10 · Emotions
What this study did
NCT04396938 · University of Oxford
2017-05-10 – 2019-08-30 · Healthy
What this study did
NCT00720473 · Mclean Hospital
2006-04 – 2011-12 · Bipolar Depression
What this study did
NCT00243152 · Pain and Analgesia Imaging and Neuroscience Group
2005-10 – 2008-07 · Facial Neuropathy
What this study did
NCT00901407 · Louisiana State University Health Sciences Center in New Orleans
2003-12 – 2007-04 · Unipolar Depression
What this study did
NCT00284791 · MaineHealth
2006-01 – 2007-02 · Adolescent Depression
What this study did
NCT00203229 · Thomas Jefferson University
2003-06 – 2006-07 · Trigeminal Neuralgia
What this study did
Used as active comparator (6)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Bipolar Disorder
NCT00274677 · GlaxoSmithKline
2003-11 – 2005-08 · Bipolar Disorder
What this study did
Epilepsy
NCT00280059 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2006-08 – 2010-04 · Epilepsy, Partial
What this study did
Phase 1 (1)
Bipolar Disorder
NCT02081287 · San Diego Veterans Healthcare System
2014-05 – 2018-07-30 · Bipolar Disorder, Manic Depression
What this study did
Phase 4 (3)
Bipolar Disorder
NCT06184581 · University Hospital Bispebjerg and Frederiksberg
2024-05-08 – 2027-12-01 · Bipolar II Disorder
What this study did
Epilepsy
NCT05697614 · Dr Cipto Mangunkusumo General Hospital
2023-03-01 – 2023-06-30 · Drug Resistant Epilepsy
What this study did
Other / comorbidity
NCT00926835 · Ministry of Health & Welfare, Korea
2009-05 – 2015-07 · Major Depressive Disorder
What this study did
Appears in other studies (5)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Bipolar Disorder
NCT01674010 · OPKO Health, Inc.
2012-08 – 2014-06 · Bipolar 1 Disorder
What this study did
Phase 4 (3)
Epilepsy
NCT00855738 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2007-05 – 2009-06 · Focal Epilepsy
What this study did
Other / comorbidity
NCT04523935 · Sathbhavana Brain Clinic
2005-12-07 – 2020-08-04 · Cerebral Palsy, Excessive Crying, Pain
What this study did
NCT03161509 · Rambam Health Care Campus
2017-07-01 – 2019-01-01 · Bariatric Surgery Candidate
What this study did
Early phase / not applicable (1)
Bipolar Disorder
NCT00531518 · MaineHealth
2007-10 – 2013-09 · Schizophrenia, Bipolar Disorder, Depression, Psychotic Disorders
What this study did

Competitive landscape

6 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Epilepsy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Lamotrigine: this drugApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00088452: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Ethosuximide 81/154 | Lamotrigine 43/146 vs Valproic Acid 85/146 missed
NCT01431976: Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP) (Week 12 of the Maintenance Phase (up to Study Week 50)): Lamotrigine 7/20
BrivaracetamApprovedSmall moleculeSynaptic vesicle glycoprotein 2A (SV2A)Partial signalNo reviewed efficacy summary in this indication
Cannabidiol (Epidiolex)ApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidPartial signal
NCT02544763: Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16): GWP42003-P 25 mg/kg/Day -43.36 percent change (IQR -67.8 to -13.6) | GWP42003-P 50 mg/kg/Day -36.55 percent change (IQR -67 to -5.5) vs Placebo -20.08 percent change (IQR -47.1 to 3.1)
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
CarbamazepineApprovedSmall moleculeSodium channelsnot yet gradedNo reviewed efficacy summary in this indication
Cenobamate (Xcopri)ApprovedSmall moleculeSodium channels + GABA-A receptorsWeak signal
NCT03678753: USA and Rest of World (RoW): Percent Change in PGTC Seizure Frequency Per 28 Days During the Double-blind Treatment Period Relative to Baseline. (Baseline and 22-week Double-blind Treatment Period.): Cenobamate -71.9% (range -100 to 273) vs Placebo -39.61% (range -100 to 211.8)
NCT04557085: Median percent change in 28-day focal seizure frequency, 6-week maintenance phase: placebo -25.9% vs cenobamate 100 mg -42.6%, 200 mg -78.3%, 400 mg -100% (all p<.001; Epilepsia 2026)
Clobazam (Onfi)ApprovedSmall moleculeGABA-A receptorReliable signal
NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100)
NCT01160770: Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment (Baseline to month 36): Clobazam 92.3 percentage of drop seizures (range -588 to 100)
Clobazam (Sympazan)ApprovedSmall moleculeGABA-A receptor (benzodiazepine site)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Diastat)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valium)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valtoco)ApprovedSmall moleculeGABA-A receptorWeak signalFeatured results are non-efficacy only in this race
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Eslicarbazepine Acetate (Aptiom)ApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT02484001: Primary endpoint (retention time / probability of ESL withdrawal) at 24 months: 0.0638 (95% CI 0.0292-0.1366) in the ESL/ESL group vs 0.0472 (95% CI 0.0180-0.1210) in the CBZ-CR/ESL group
NCT00988156: Change From Baseline in Seizure Frequency (Baseline up to Visit 7): Esl (BIA 2-093) 36.6 seizures/month (Standard Deviation 72.47) vs Placebo 62 seizures/month (Standard Deviation 186.19) missed
EthosuximideApprovedSmall moleculeT-type calcium channelReliable signal
NCT00088452: Freedom from treatment failure at 16–20 weeks: 81/154 ethosuximide vs 43/146 lamotrigine, odds ratio 2.66 (95% CI 1.65–4.28; p<0.001); ethosuximide vs valproic acid: 81/154 vs 85/146, with no direct statistical comparison posted.
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Reliable signal
NCT01713946: Primary 1, response rate (≥50% seizure-frequency reduction) in the maintenance period: placebo 15.1%, low-exposure everolimus 28.2% (p=0.0077), high-exposure everolimus 40.0% (p<0.0001), met for both doses. Primary 2, median percentage reduction in seizure frequency: placebo 14.9%, low exposure 29.3% (p=0.0028), high exposure 39.6% (p<0.0001), met for both doses.
FelbamateApprovedSmall moleculeNMDA receptor (glycine site, antagonist)not yet gradedNo reviewed efficacy summary in this indication
Fenfluramine (Fintepla)ApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
FosphenytoinApprovedSmall moleculeVoltage-gated sodium channelPartial signalNo reviewed efficacy summary in this indication
GabapentinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsPartial signal
NCT00007670: VA Cooperative Study 428 (18 centers, 593 elderly patients with new-onset seizures), matching this trial's title/sponsor/design exactly. Primary endpoint (12-month trial retention): early-termination rates were gabapentin 51%, lamotrigine 44.2%, carbamazepine 64.5% (p=0.0002); gabapentin significantly outperformed carbamazepine (p=0.008) but was not shown superior to lamotrigine. Seizure control was similar across all three arms.
NCT00603473: Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures (12 weeks): Gabapentin -0.158 ratio (95% CI -0.221 to -0.096)
GanaxoloneApprovedSmall moleculeGABA-A receptorPartial signal
NCT04391569: Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes): Ganaxolone 79.59% (95% CI 65.657 to 89.755) vs Placebo 12.77% (95% CI 4.832 to 25.741)
NCT01963208: Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period (Baseline and Week 14): Double Blind: Cohort 2 - Ganaxolone -21.28 Percent change (95% CI -29.6 to -14.29) | Double Blind: Cohort 2 - Placebo -10.25 Percent change (95% CI -20.14 to -1.28) missed
Lacosamide (Vimpat)ApprovedSmall moleculeVoltage-gated sodium channelsReliable signal
NCT00136019: Median % reduction in seizure frequency/28 days: lacosamide 400mg/day -37.3% (p=0.008), 600mg/day -37.8% (p=0.006), vs placebo -20.8%; >=50% responder rates 38.3% (400mg) and 41.2% (600mg) vs 18.3% placebo (p<0.001).
NCT02408523: Primary endpoint, time to second PGTC seizure over 24 weeks: hazard ratio 0.540 (95% CI 0.377 to 0.774), p<0.001, lacosamide vs placebo (CT.gov posted results; 49 vs 76 patients with a second PGTC seizure).
Levetiracetam (Elepsia XR)
ApprovedUS marketing discontinued
Small moleculeSynaptic vesicle glycoprotein 2A (SV2A)not yet gradedNo reviewed efficacy summary in this indication
Levetiracetam (Keppra XR)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signalFeatured results are non-efficacy only in this race
Levetiracetam (Keppra)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signal
NCT00150709: Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period (During the Treatment Period (an average of 2 years), compared to Baseline): N159 PBO/LEV -66.4 percentage of change (IQR -90 to -22.3) | N159 LEV/LEV -47.8 percentage of change (IQR -76.2 to -25.4) | N01010+N151 LEV/LEV -66.4 percentage of change (IQR -93.6 to -5.6)
NCT00615615: Partial-onset seizure frequency per week during the 14-week treatment period (primary endpoint): 26.8% greater reduction with levetiracetam vs placebo (p=0.0002, 95% CI 14.0-37.6%); 50%-responder rate 44.6% (45/101) LEV vs 19.6% (19/97) placebo (p=0.0002).
LorazepamApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Midazolam (Nayzilam)ApprovedSmall moleculeGABA-A receptor, GABA-A receptor (benzodiazepine site)Reliable signal
NCT01390220: Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67
NCT01999777: Number of Participants That Were Seizure-free (6 hours): USL261 17/31 vs Placebo 12/31 missed
Oxcarbazepine (Oxtellar XR)ApprovedSmall moleculeVoltage-gated sodium channelPartial signalFeatured results are non-efficacy only in this race
Oxcarbazepine (Trileptal)ApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00050934: Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047.
Perampanel (Fycompa)ApprovedSmall moleculeAMPA receptor (antagonist)Weak signal
NCT01393743: Core study: median percent change in PGTC seizure frequency per 28 days, perampanel -76.5% vs placebo -38.4%, median difference -30.8 (95% CI -45.5 to -15.2), p=0.0001; 50% responder rate in maintenance 64.2% vs 39.5%, p=0.0019 (n=81 each) (CT.gov posted results).
NCT00699582: Median percent change in 28-day seizure frequency: placebo -9.7%, perampanel 8 mg -30.5% (p<0.001), 12 mg -17.6% (p=0.011); 50% responder rate 14.7%, 33.3% (p=0.002) and 33.9% (p<0.001) (Study 305, Epilepsia 2013).
Phenobarbital Sodium Injection (Sezaby)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
PhenytoinApprovedSmall moleculeVoltage-gated sodium channelsnot yet gradedNo reviewed efficacy summary in this indication
PregabalinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsWeak signal
NCT01747915: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase (Day 1 up to Week 12): Pregabalin 5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day 1.17 Seizure per 28 days (Standard Error 0.097) | Pregabalin 10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day 1.13 Seizure per 28 days (Standard Error 0.095) vs Placebo 1.14 Seizure per 28 days (Standard Error 0.098) missed
PrimidoneApprovedSmall molecule—not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
RufinamideApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT00334958: Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis).
StiripentolApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
TiagabineApprovedSmall moleculeGABA transporter (uptake carrier)not yet gradedNo reviewed efficacy summary in this indication
Topiramate (Eprontia)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Qudexy XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydraseReliable signal
NCT01142193: Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): USL255 39.5 Percent Reduction (range -227.3 to 100) | Placebo 21.65 Percent Reduction (range -531.2 to 100)
Topiramate (Topamax Sprinkle)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Topamax)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasePartial signal
NCT00113815: Primary endpoint, median % reduction from baseline in daily partial-onset-seizure rate (video-EEG): topiramate 25 mg/kg 20.4% vs placebo 13.1% (p=0.97); 15 mg/kg dose p=0.97 vs placebo; 5 mg/kg dose p=0.91 vs placebo -- no dose significantly better than placebo. missed
NCT00236756: Topiramate add-on in Lennox-Gastaut syndrome: median percentage reduction from baseline in average monthly seizure rate 14.8% with topiramate versus a -5.1% increase with placebo; a >=50% reduction from baseline in major seizures (drop attacks and tonic-clonic seizures) was reached by 33% of the topiramate group versus 8% of the control group.
Topiramate (Trokendi XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Valproate
ApprovedUS marketing discontinued
Small moleculeGABAergic neurotransmissionPartial signal
NCT00004817: Phase III NINDS trial (Temkin et al.): valproate did not reduce early or late post-traumatic seizure rates vs phenytoin control, and showed a trend toward higher mortality (13.4% vs 7.2%). missed
Vigabatrin (Sabril)ApprovedSmall moleculeGABA transaminase (GABA-T)Partial signal
NCT02849457: Cognitive Assessment Scores and Developmental Impact (24 months): Delayed Vigabatrin (Placebo) 83.9 score on a scale ± 17.3 vs Early Vigabatrin 80.9 score on a scale ± 15.6 vs Watchful Waiting (Control Group) 97.3 score on a scale ± 16.9 vs Watchful Waiting (Open Label Vigabatrin) 85.0 score on a scale ± 21.6; p=0.8681 (Delayed Vigabatrin (Placebo) vs Early Vigabatrin) missed
Vigabatrin (Vigafyde)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
Zonisamide (Zonegran)ApprovedSmall moleculeVoltage-gated sodium channelsWeak signalFeatured results are non-efficacy only in this race
Zonisamide (Zonisade)ApprovedSmall moleculeVoltage-gated sodium and T-type calcium channelsnot yet gradedNo reviewed efficacy summary in this indication
AzetukalnerPhase 3Small moleculeKv7 potassium channelReliable signal
NCT05614063: Median % reduction in monthly focal seizure frequency at Week 12 (X-TOLE2, double-blind period): 25 mg dose -53.2% vs placebo -10.4%; 15 mg dose -34.5% vs placebo -10.4%
BexicaserinPhase 3Small moleculeSerotonin 5-HT2C receptor (agonist)Partial signal
NCT05364021: Primary endpoint, median percentage change in countable motor seizures over the treatment period: bexicaserin -59.8% (n=35) vs placebo -17.4% (n=9), difference 42.4%, p = .0538 (not statistically significant) (PACIFIC, Epilepsia 2026). missed
CarisbamatePhase 3Small moleculeVoltage-gated sodium channelPartial signal
NCT00425282: Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results).
NCT00433667: Primary endpoint, responder rate (at least 50% reduction in partial-onset seizure frequency, double-blind phase vs baseline): carisbamate 400 mg 23.8% and 200 mg 23.1% vs placebo 21.3%; difference 2.48 points (95% CI -6.04 to 11), P = 0.553 (400 mg) and 1.84 points (95% CI -6.58 to 10.26), P = 0.637 (200 mg) (pre-specified CMH tests, EU Clinical Trials Register results). missed
Clemizole (EPX-100)Phase 3Small moleculeHistamine H1 receptor, Serotonin receptors (5-HT)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Libervant)Phase 3Small moleculeGABA-A receptorWeak signalFeatured results are safety only in this race
ElsunersenPhase 3RNA / oligonucleotideSCN2A (antisense knockdown)Partial signal
NCT05737784: Part A (randomized 3:1, sham-controlled, 9 patients): 77% placebo-adjusted seizure reduction from baseline (p=0.015) (Praxis, 2026-04-06).
RAP-219Phase 3Small moleculeAMPA receptor (TARP γ8-dependent)Weak signal
NCT06377930: Primary endpoint met: 85.2% of patients achieved ≥30% reduction in long episodes (LEs) from baseline (p<0.0001); 72.0% achieved ≥50% reduction in clinical seizures (p<0.0001)
RelutriginePhase 3Small moleculeVoltage-gated sodium channel (persistent current)not yet gradedNo reviewed efficacy summary in this indication
Staccato AlprazolamPhase 3Small moleculeGABA-A receptorReliable signal
NCT03478982: 1.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8); 2.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8)
VormatriginePhase 3Small moleculeVoltage-gated sodium channel (NaV1.2 / NaV1.6)Partial signal
NCT06999902: Primary success measure (reduction in focal seizure frequency over 12 weeks versus placebo) not met, per Praxis; the secondary 50% responder rate was met. The company disclosed no numbers. missed
YCJ-01Phase 3BotanicalCannabinoids (full-spectrum cannabis extract)not yet gradedNo reviewed efficacy summary in this indication
Cannabidiol (JZP926)Phase 2/3Small moleculeCannabidiol (CBD) modulates multiple targets, including the transient receptor potential vanilloid 1 (TRPV1) and the orphan G-protein-coupled receptor GPR55, cannabinoidnot yet gradedNo reviewed efficacy summary in this indication
OpakalimPhase 2/3Small moleculeKv7 potassium channelWeak signal
NCT06425159: Closed early with 27 subjects: median time to second generalized tonic-clonic seizure 141 days with opakalim vs 47 days with placebo; no formal statistical test reported (Biohaven, 2026-05-26).
ABS-1230Phase 2Small moleculeKCNT1 (KNa1.1/Slack) channelnot yet gradedNo reviewed efficacy summary in this indication
AV078Phase 2Small moleculemTORC1 (mammalian target of rapamycin complex 1) (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
BMB-101Phase 2Small moleculeSerotonin 5-HT2C receptor (biased agonist)not yet gradedNo reviewed efficacy summary in this indication
CB03-154Phase 2Small moleculeKCNQ2/3 (Kv7.2/7.3) potassium channel (opener)not yet gradedNo reviewed efficacy summary in this indication
Huperzine A (SPN-817)Phase 2Small moleculeAcetylcholinesteraseWeak signal
NCT03156439: Participants were given the experimental treatment twice a day, with the dose increased every two to three days until a maximum daily dose of 2.5 mg was reached. Participants tolerated the treatment well, with mild to moderate, transient and non-dose-limiting adverse events.
NPT2042Phase 2Small moleculeNKCC1Partial signalNo reviewed efficacy summary in this indication
AMT-260Phase 1/2Gene therapy / editingGRIK2 (GluK2-containing kainate receptor)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 66 furthest-along competitors are listed; 7 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Lamotrigine to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
June 2028 (1)
Phase 3Bipolar DisorderRecruiting
Est. primary completion 2028-06-13 · NCT06929273 · CT.gov ↗
What to watch

See the full readout calendar ↗